Between 50–80% of children with autism spectrum disorder (ASD) have insomnia, which adversely affects their mental and physical health. However, there is no consensus to-date on suitable tools for insomnia screening and monitoring in daily clinical practice. An expert panel of child neuropsychiatry and sleep specialists, with expertise in children with neurodevelopmental disabilities, recommends: (1) performing insomnia screening of all children with ASD; (2) considering discussion or referral to a sleep specialist when comorbid sleep disorders are suspected. The panel further developed structured, brief screening and monitoring tools to facilitate insomnia screening and management in daily practice, monitor treatment effectiveness and standardize and compare outcomes across clinical settings to improve care and well-being of children with ASD and their families.
Bibliografisk noteFunding Information:
All authors received conference support from Neurim Pharmaceuticals SARL for a videoconference consensus meeting related to the under consideration for publication. Dr. Banaschewski served in an advisory or consultancy role for ADHS digital, Infectopharm, Lundbeck, Medice, Oberberg GmbH, Neurim Pharmaceuticals, Roche, and Takeda. He received conference support or speaker’s fee by Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. Dr. Bruni reports personal fees and non-financial support from Neurim pharmaceuticals for advisory board consulting. Dr. Fuentes has received research support from Policlinica Gipuzkoa Foundation (PGF), Servier, and AIMS-2 Trials/Project ID 777394. He has received partial support for professional meetings attendance from PGF, ESCAP & AACAP. Dr Hill and Dr. Hvolby have nothing to report. Dr. Posserud reports Scientific Advisory Board meeting reimbursement from Takeda paid to her institution, outside the submitted work. Dr. Schroder reports personal fees and non-financial support from Neurim pharmaceuticals for advisory board consulting; lecture; travel to meeting related to the work under consideration for publication, and outside the submitted work personal fees and non-financial support from Biocodex for expert group and lectures; travel to meetings and personal fees from Takeda for lecture.
© 2021, The Author(s).